Immunomodulation Following Transfusion

PHASE4CompletedINTERVENTIONAL
Enrollment

287

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2011

Conditions
Blood Component Transfusion
Interventions
BIOLOGICAL

Standard blood components

Transfusion, if ordered by physician, with unfiltered red blood cells and apheresis platelets

BIOLOGICAL

Leukoreduced blood components

Transfusion, if ordered by a physician, of leukoreduced red blood cells and apheresis platelets

BIOLOGICAL

Leukoreduced and irradiated

Transfusion, if ordered by physician, of gamma irradiated leukoreduced red blood cells and gamma irradiated apheresis platelets

Trial Locations (2)

98133

Northwest Hospital, Seattle

98195

University of Washington Medical Center, Seattle

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

Bloodworks

OTHER

lead

University of Washington

OTHER

NCT00810810 - Immunomodulation Following Transfusion | Biotech Hunter | Biotech Hunter